|
|
11.06.25 - 15:06
|
Aptatek BioSciences, Inc. Announces Bridge Financing to Support Advancement of the PheCheck™ Aptamer-based In-home Monitoring Platform (Business Wire)
|
|
PRINCETON, N.J.--(BUSINESS WIRE)--Aptatek BioSciences, Inc., a pioneer in developing innovative in-home monitoring solutions for patients managing chronic diseases, today announced it has received bridge financing from Canterbury Scientific, Ltd, a current strategic investor. This latest funding tranche follows the successful advancement of Aptatek's PheCheck™ platform, an FDA breakthrough diagnostic device designed for at-home monitoring of phenylalanine levels in patients with phenylketonuria (PKU).
The new financing supports Aptatek's ongoing clinical development and accelerates its path toward commercialization of its DNA aptamer-based home monitor for PKU, a genetic metabolic disorder, requiring diligent monitoring of phenylalanine levels to prevent serious health complications. As with diabetes management, maintaining optimal phenylalanine levels through diet and medication is essential for patient health and quality of life.
“This further funding from Canterbury Scientific strengthens our abi...
|
|
|
|
|
|
|
|
|
|
|
|
10.12.24 - 13:48
|
Aptahem′s Scientific Manuscript now Published in the British Journal of Pharmacology (Cision)
|
|
Aptahem announced on 10 September 2024 that their scientific manuscript had been accepted for publication in the British Journal of Pharmacology (BJP). On the 9th December 2024, the article has been published.
Read the article, titled “Antithrombotic but not anticoagulant activity of the thrombin-binding RNA aptamer Apta-1”, via this link (https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.17382). The article describes the results of the preclinical and mechanistic studies that have been performed by Aptahem and in a collaboration during several years with Örebro University. The study...
|
|
|
|
|
|
|
|
|